Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

23andMe to Disable API Access to Outside App Developers: Report

23andMe will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported.

Read More »

Cashing in on DNA: race on to unlock value in genetic data

As millions of people pay for home tests to check on ancestry or health risks, genetic data is becoming an increasingly valuable resource for drugmakers, triggering a race to create a DNA marketplace.

Read More »

Regeneron forms consortium to accelerate gene sequencing project

Regeneron Pharmaceuticals Inc. announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project the company believes could help accelerate new drug discovery and improve approval success rates.

Read More »

23andMe Begins Enrollment for First-of-its-Kind Study on Major Depressive and Bipolar Disorders

23andMe, working in collaboration with the Milken Institute and Lundbeck, announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders.

Read More »

Philips in deals with U.S. hospitals on use of its gene data platform for cancer research

Dutch healthcare technology company Philips said Thursday it had reached deals with New York’s Memorial Sloan Kettering Cancer Center (MSK) and Utah-based Intermountain Healthcare for them to use its genomics platform for cancer research and treatment.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom